2-[(1-苄基哌啶-4-基)甲氧基]-5-溴吡啶 | 1010114-44-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 2-[(1-苄基哌啶-4-基)甲氧基]-5-溴吡啶
• 英文名称: 2-[(1-benzylpiperidin-4-yl)methoxy]-5-bromopyridine
• CAS: 1010114-44-9
• 化学式: C₁₈H₂₁BrN₂O
• 分子量: 361.282
• InChiKey: HEGZWNJQOVCJEI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  25.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-[(1-苄基哌啶-4-基)甲氧基]-5-溴吡啶 在 isopropyl magnesium chloride - lithium chloride complex 、 盐酸羟胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 3.0h， 生成 (E)-1-{6-[(1-benzylpiperidin-4-yl)methoxy]pyridin-3-yl}-N-hydroxymethanimine hydrochloride
  参考文献：
  名称：

  Design, synthesis, and characterization of novel, nonquaternary reactivators of GF-inhibited human acetylcholinesterase

  摘要：

  The goal of this research was to identify structurally novel, non-quaternarypyridinium reactivators of GF (cyclosarin)-inhibited hAChE that possess the capacity to mediate in vitro reactivation of GF-inhibited human acetylcholinesterase (hAChE). New compounds were designed, synthesized and assessed in GFinhibited hAChE assays. Structure activity relationships for AChE binding and reactivation of GF-inhibited hAChE were developed. Lead compounds from two different chemical series, represented by compounds 17 and 38, displayed proficient in vitro reactivation of GF- inhibited hAChE, while also possessing low inhibition of native enzyme. (c) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.02.049
• 作为产物：
  描述：

  1-苄基-4-哌啶甲酸乙酯 在 lithium aluminium tetrahydride 、 sodium hydride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.08h， 生成 2-[(1-苄基哌啶-4-基)甲氧基]-5-溴吡啶
  参考文献：
  名称：

  Design, synthesis, and characterization of novel, nonquaternary reactivators of GF-inhibited human acetylcholinesterase

  摘要：

  The goal of this research was to identify structurally novel, non-quaternarypyridinium reactivators of GF (cyclosarin)-inhibited hAChE that possess the capacity to mediate in vitro reactivation of GF-inhibited human acetylcholinesterase (hAChE). New compounds were designed, synthesized and assessed in GFinhibited hAChE assays. Structure activity relationships for AChE binding and reactivation of GF-inhibited hAChE were developed. Lead compounds from two different chemical series, represented by compounds 17 and 38, displayed proficient in vitro reactivation of GF- inhibited hAChE, while also possessing low inhibition of native enzyme. (c) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.02.049

文献信息

• New compounds
  申请人：Brandt Peter

  公开号：US20080103123A1

  公开（公告）日：2008-05-01

  The present invention relates to compounds of Formula (Ia) and pharmaceutically acceptable salts, hydrates, geometrical isomers, racemates, tautomers, optical isomers and N-oxides thereof, wherein one of W 1 and W 2 is N and the other is CR 12 . The invention also relates to pharmaceutical compositions comprising these compounds, and to the use of these compounds for the prophylaxis and treatment of medical conditions relating to disorders of the G-protein-coupled receptor GPR119, such as diabetes and obesity.

  本发明涉及式(Ia)化合物及其药物可接受的盐、水合物、几何异构体、外消旋体、互变异构体、光学异构体和N-氧化物，其中W1和W2中的一个是N，另一个是CR12。本发明还涉及包含这些化合物的药物组合物，以及使用这些化合物预防和治疗与G蛋白偶联受体GPR119的紊乱相关的医疗状况，如糖尿病和肥胖症。
• PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS
  申请人：BIOVITRUM AB (publ)

  公开号：EP2059516A1

  公开（公告）日：2009-05-20
• [EN] PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS<br/>[FR] COMPOSÉS DE PYRIDINE PERMETTANT DE TRAITER LES TROUBLES LIÉS À GPR119
  申请人：BIOVITRUM AB PUBL

  公开号：WO2008025798A1

  公开（公告）日：2008-03-06

  [EN] The present invention relates to compounds of Formula (Ia) and pharmaceutically acceptable salts, hydrates, geometrical isomers, racemates, tautomers, optical isomers and N-oxides thereof, wherein one of W¹ and W² is N and the other is CR¹². The invention also relates to pharmaceutical compositions comprising these compounds, and to the use of these compounds for the prophylaxis and treatment of medical conditions relating to disorders of the G-protein-coupled receptor GPRl 19, such as diabetes and obesity.
  [FR] L'invention concerne des composés de formule (Ia) et leurs sels, hydrates, isomères géométriques, racémates, tautomères, isomères optiques et N-oxydes pharmaceutiquement acceptables, W¹ et W² représentant N et l'autre représentant CR¹². L'invention concerne également des compositions pharmaceutiques renfermant lesdits composés et l'utilisation desdits composés pour la prophylaxie et le traitement de pathologies médicales relatives à des troubles du récepteur de GPR119 couplé à la protéine G, tels que le diabète et l'obésité.
• Design, synthesis, and characterization of novel, nonquaternary reactivators of GF-inhibited human acetylcholinesterase
  作者：Stanton F. McHardy、Jonathan A. Bohmann、Michael R. Corbett、Bismarck Campos、Michael W. Tidwell、Paul Marty Thompson、Chris J. Bemben、Tony A. Menchaca、Tony E. Reeves、William R. Cantrell、William E. Bauta、Ambrosio Lopez、Donald M. Maxwell、Karen M. Brecht、Richard E. Sweeney、John McDonough

  DOI：10.1016/j.bmcl.2014.02.049

  日期：2014.4

  The goal of this research was to identify structurally novel, non-quaternarypyridinium reactivators of GF (cyclosarin)-inhibited hAChE that possess the capacity to mediate in vitro reactivation of GF-inhibited human acetylcholinesterase (hAChE). New compounds were designed, synthesized and assessed in GFinhibited hAChE assays. Structure activity relationships for AChE binding and reactivation of GF-inhibited hAChE were developed. Lead compounds from two different chemical series, represented by compounds 17 and 38, displayed proficient in vitro reactivation of GF- inhibited hAChE, while also possessing low inhibition of native enzyme. (c) 2014 Elsevier Ltd. All rights reserved.